Use of reduced dose of OKT3 (2.5 mg) after renal transplantation.

MONOCLONAL anti-CD3 antibodies have been widely used for the treatment of acute allograft rejection (AR) episodes and for induction therapy (IT). Their impact on long-term survival has been demonstrated mainly in high-risk patients. Recent data have suggested that this antibody may be used at reduced doses without compromising its efficacy. We report here our experience with 58 kidney transplant (Tx) patients in which low daily doses of OKT3 were used as IT or for the treatment of severe or steroid-resistant AR.